Researchers in Dr. Dean Felsher's lab have generated a murine hepatocellular carcinoma (HCC) cell line with controllable MYC expression. HCC is one of the most common and incurable malignancies.
Stanford researchers have developed a system for precise genetic modification of human embryonic stem cells (ECSs) and induced pluripotent stem cells (iPSCs).
Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pbx1a monoclonal antibodies to study transcriptional regulation, embryonic development, and tissue homeostasis.
Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pbx3a monoclonal antibodies to study transcriptional regulation and embryonic development.
Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pbx3b monoclonal antibodies to study transcriptional regulation and embryonic development.
Researchers in the laboratory of Dr. Michael Cleary at Stanford University have developed anti-Pknox monoclonal antibodies to study transcriptional regulation, embryonic development, and tissue homeostasis.
Soluble CD81 molecules were constructed for the purpose of identifying a postulated ligand to CD81. Recently CD81 has been claimed by others to be a candidate for a receptor for the human hepatitis C virus (HCV).
This antibody is directed against the human LMO2 antigen, which is expressed as a transcription factor in certain lymphomas and leukemias. We have recently shown that it identifies those lymphomas derived from germinal center B cells.
Researchers in Dr. Shoshana Levy's lab have created a pro B cell lines that provides the first B cell lineage tumors in a C57BL mouse strain. The cell lines, known as H11 and 2F3, were made by transducing mouse bone marrow with BCR-ABL retrovirus.
We have recently shown that rab9 plays a key role in the transport of proteins between late endosomes and the trans Golgi network. Purified, recombinant, rab9 protein stimulated transport in a cell free system that reconstitutes this event.
RNKp30 monoclonal antibodies were generated by immunizing BALB/c mice with rNKp30-Fc fusion protein. The rNKp30-Fc fusion protein is a soluble protein consisting of the extracellular domain of rNKp30 fused to the Fc domain of human IgG1.
Monoclonal antibody that recognizes MLL, an oncoprotein that is mutated in a broad subset of pediatric and adult leukemias. MLL protein displays histone methyltransferase activity.